<SEC-DOCUMENT>0001628280-24-027704.txt : 20240611
<SEC-HEADER>0001628280-24-027704.hdr.sgml : 20240611
<ACCEPTANCE-DATETIME>20240611172801
ACCESSION NUMBER:		0001628280-24-027704
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240611
FILED AS OF DATE:		20240611
DATE AS OF CHANGE:		20240611

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYBIN INC.
		CENTRAL INDEX KEY:			0001833141
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40673
		FILM NUMBER:		241036849

	BUSINESS ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
		BUSINESS PHONE:		(908) 764-8385

	MAIL ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>cybininc-form6xk06x11x2024.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i6e796a3a03ba4f83b223f64f343b6ee4_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Washington, D.C. 20549</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Form 6-K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the month of June, 2024.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commission File Number&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">001-40673</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Cybin Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Exact Name of Registrant as Specified in Charter)<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Address of principal executive offices) </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form 20-F  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:115%">&#9633;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  Form 40-F &#8864;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURE</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:5.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CYBIN INC.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Registrant)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June 11, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#47;s&#47; Doug Drysdale&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Doug Drysdale</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">EXHIBIT INDEX</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="a06-11x2024svpclinicaldeve.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">News Release dated June 11, 2024</a></font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a06-11x2024svpclinicaldeve.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ib4e7aba9954342a5a8a03d20373b90c7_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">  </font></div><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:120px;margin-bottom:5pt;vertical-align:text-bottom;width:206px"></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:133%">Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">- Dr. Mahableshwarkar, a Board-Certified Psychiatrist, is an experienced pharmaceutical industry leader with decades of expertise in drug development -</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%"><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">TORONTO, CANADA </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8211; June 11, 2024 &#8211; </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">Cybin Inc.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> (NYSE American&#58;CYBN) (Cboe CA&#58;CYBN) (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Cybin</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8221;), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, is pleased to announce that Dr. Atul R. Mahableshwarkar M.D., DLFAPA, has joined the Company as Senior Vice President, Clinical Development. Dr. Mahableshwarkar will lead the development of the CYB003 program, Cybin&#8217;s proprietary deuterated psilocybin analog which has received U.S. Food and Drug Administration (&#8220;FDA&#8221;) Breakthrough Therapy Designation for the adjunctive treatment of major depressive disorder.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8220;We are delighted to welcome Dr. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Mahableshwarkar to the Cybin team at this critical juncture in the Company&#8217;s progression</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">,&#8221; said Amir Inamdar, Chief Medical Officer of Cybin. &#8220;As we approach the initiation of our Phase 3 study of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">CYB003, Dr. Mahableshwarkar&#8217;s deep experience of successfully running global Phase 3 programs will be invaluable. His broad expertise across strategic, developmental and regulatory domains will no doubt contribute to accelerating Cybin&#8217;s path forward,&#8221; concluded Dr. Inamdar.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8220;With the imminent commencement of its Phase 3 study of CYB003, and the initiation of a Phase 2 study of CYB004, the Company&#8217;s proprietary deuterated dimethyltryptamine (&#8220;DMT&#8221;) program for the treatment of Generalized Anxiety Disorder (&#8220;GAD&#8221;), this is an exciting time for Cybin,&#8221; stated Dr. Mahableshwarkar. &#8220;I am extremely encouraged by the recently published positive data across the Company&#8217;s lead pipeline products and believe that my experience overseeing smaller Proof-of-Principal&#47;Concept as well as large, complex, global Phase 3 trials will contribute to Cybin&#8217;s success advancing its portfolio of candidates. I share Cybin&#8217;s commitment to bringing forward improved therapeutics for patients who suffer with mental health disorders and look forward to contributing to the team&#8217;s efforts,&#8221; concluded Dr. Mahableshwarkar.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Dr. Mahableshwarkar is a board-certified psychiatrist and experienced drug development executive with experience in both large global and small startup companies. He brings varied experiences from academia and industry as a site principal investigator for industry-sponsored studies and has submitted several INDs and NDAs leading to drug approvals. With a focus on drug development strategy and oversight, he has designed and conducted global clinical trials in Alzheimer&#8217;s disease, anxiety disorders, bipolar disorder, major depression, Parkinson&#8217;s Disease and schizophrenia and led the development program resulting in the approval of a novel antidepressant.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Dr. Mahableshwarkar graduated from the Armed Forces Medical College in India and completed a residency in Psychiatry and a fellowship in Neuropsychiatry from The Rosalind Franklin University of Health Sciences&#47;The Chicago Medical School, where he was an Associate Professor and Vice Chair of the Department of Psychiatry and Behavioral Sciences. He also led the Mental Health Services Product Line at the North Chicago VAMC, where he managed the mental health care for veterans. He has more than 180 scientific publications&#47;posters&#47;oral presentations to his credit.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">About Cybin</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin&#8217;s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland.  For company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Cautionary Notes and Forward-Looking Statements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as &#8220;may&#8221;, &#8220;should&#8221;, &#8220;could&#8221;, &#8220;intend&#8221;, &#8220;estimate&#8221;, &#8220;plan&#8221;, &#8220;anticipate&#8221;, &#8220;expect&#8221;, &#8220;believe&#8221; or &#8220;continue&#8221;, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company&#8217;s plan to initiate a Phase 3 trial for CYB003 around mid-year 2024&#59; the Company&#8217;s Phase 2 trial for CYB004&#59; and the Company&#8217;s proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include&#58; implications of the spread of COVID-19 on the Company's operations&#59; fluctuations in general macroeconomic conditions&#59; fluctuations in securities markets&#59; expectations regarding the size of the psychedelics market&#59; the ability of the Company to successfully achieve its business objectives&#59; plans for growth&#59; political, social and environmental uncertainties&#59; employee relations&#59; the presence of laws and regulations that may impose restrictions in the markets where the Company operates&#59; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2023, and the Company&#8217;s annual information form for the year ended March 31, 2023, which are available under the Company's profile on </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">www.sedarplus.ca</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> and with the U.S. Securities and Exchange Commission on EDGAR at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">www.sec.gov</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin makes no medical, treatment or health benefit claims about Cybin&#8217;s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin&#8217;s performance and operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">Neither the Cboe Canada nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Investor &#38; Media Contact&#58;&#160;</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Gabriel Fahel</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Chief Legal Officer</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin Inc.</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1-866-292-4601</font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">irteam&#64;cybin.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> &#8211; or &#8211; </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">media&#64;cybin.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font><br></font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
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MJ=FF'[^6 4Y!$M6S2.(*F2Q!IG<O0LZP'1[XVJ;Y:!_]N Y+EB8G;$K6CTV
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M@$. SIYBF_S;$.BG'/-K9'G$F$)HAH1Y$W!L[$%4<1[R 72_<MRAR!.KMN[
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M*LZ\ MP # LU* <]D%W@.P%KT9HPOP+^A_Q91B %,V(ET$T58]WD^/Y%D48
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M+V&Z]AY+P_>1 *-G8\+OFGT!22ZA6T[UPV&30 TSD%)R6C>EPY7B0+JEF G
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HR)) 9V &\ QP'C QVNB,,::*_P,XN9"3FUCC]     !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
